Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd has disclosed the voting results of its 33rd Annual General Meeting (AGM), which was held on August 21, 2026, through video conference. The meeting approved all 7 resolutions, including the appointment of a new director and the adoption of audited standalone financial statements for the financial year ended March 31, 2026.

Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd held its 33rd Annual General Meeting on August 21, 2026, through video conferencing, with 75 members in attendance. The meeting was chaired by Mr. Chandra Mouliswar Reddy Gangavaram, Whole-time Director. The company secretary read out the notice of AGM and board's report, and the meeting concluded at 11:15 AM.

Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd has published a notice of its 33rd Annual General Meeting (AGM) scheduled to be held on 21st August, 2026, through a newspaper advertisement.

Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd has announced the book closure and cut-off date for its 33rd Annual General Meeting (AGM) to be held on August 21, 2026. The register of members and share transfer books will be closed from August 15 to 21, 2026, and the company has fixed August 14, 2026, as the cut-off date for remote e-voting.

Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd has submitted its 33rd Annual Report for the financial year 2025-26, as per SEBI (LODR) Regulations, 2015. The report is available on the company's website and the Annual General Meeting is scheduled for August 21, 2026.

Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd submitted a notice of its 33rd Annual General Meeting for the financial year 2025-26, scheduled to be held on August 21, 2026, through video conferencing. The meeting will consider and adopt the audited financial statements for the year ended March 31, 2026, and appoint a director in place of Mr. Balasubba Reddy Mamilla, who retires by rotation.

Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd has announced the appointment of M/s. PCR & Associates as Cost Auditors for the FY 2026-27. The company has also approved the re-constitution of the POSH Committee and announced unaudited financial results for the quarter ended 30.06.2026.

Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd has announced its un-audited financial results for the quarter ended 30.06.2026, with revenue from operations at ₹3,699.69 lakhs and profit before exceptional items and tax at ₹(250.73) lakhs. The company has also appointed M/s. PCR & Associates as cost auditors for the FY 2026-27 and re-constituted its POSH Committee.

Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd has announced its unaudited financial results for the quarter ended 30.06.2026, with a profit before exceptional items and tax of ₹250.73 lakhs, and a net profit of ₹-250.73 lakhs. The company has also approved the re-constitution of the POSH Committee and appointed M/s. PCR & Associates as Cost Auditors for FY 2026-27.

Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd has postponed its board meeting scheduled for July 25, 2026, to July 27, 2026, to consider and approve unaudited financial results for the quarter ended June 30, 2026, and a limited review report for the same period.

Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/07/2026 to consider and approve unaudited financial results for the quarter ended June 30, 2026, limited review report for the quarter ended June 30, 2026, and any other business with the permission of the Chair.